Research
Hormonal
Niacin is no longer recommended for routine use in type 2 diabetes because large clinical trials failed to show significant cardiovascular benefits despite improving lipid parameters.
Do not use niacin to treat high triglycerides or low HDL in type 2 diabetes. Large studies show it does not reduce heart attacks or death, and it may worsen blood sugar control. Stick to statins and fibrates if needed.
StrongRefutesVERY_HIGH confidence
Evidence for the use of niacin has been challenged by non-significant CVD outcomes in two recent large clinical trials.
Why this rating
Based on two large, definitive clinical trials (AIM-HIGH, HPS2-THRIVE).
Source
Origin and therapy for hypertriglyceridaemia in type 2 diabetes
Jing Pang et al. · World Journal of Diabetes · 2014
DOI 10.4239/wjd.v5.i2.165
narrative_reviewCited 23×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Statin therapy is the first-line treatment for dyslipidemia in type 2 diabetes, significantly reducing cardiovascular events, although it only modestly lowers triglycerides.Strong
- Modest weight loss (5%-10%) in type 2 diabetes significantly lowers plasma triglyceride levels (up to 25%) and normalizes postprandial triglyceride concentrations.Good
- Fibrates (specifically fenofibrate) are effective adjunctive treatments for lowering triglycerides and reducing cardiovascular events in type 2 diabetic patients with high triglycerides and low HDL.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →